MDP2P

Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)

Retrieved on: 
Monday, April 15, 2024
Ground substance, Good manufacturing practice, Psychedelic drug, Drug development, MDP2P, Health Canada, Conference, API, MDMA, Science, Tel Aviv University, EST, Good, GMP, FRA, Fine chemical

VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.

Key Points: 
  • VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.
  • As previously communicated in January , Optimi employed the precursor 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) to guarantee the quality and uniformity of the MDMA API manufacturing process.
  • The production of this MDMA API was produced in-house, explicitly for the recently disclosed supply agreement with the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel.
  • Bill Ciprick, CEO of Optimi, confirms that the MDMA was tested and validated by a third-party laboratory, therefore meeting the Company’s quality assurance standards.

Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats

Retrieved on: 
Wednesday, January 3, 2024
Physician, MAPS, FDA, FRA, NDA, MDMA, GMP, New Drug Application, Chromatography, American Medical Association, COA, Health Canada, HPLC, Safety, MDP2P, Pharmaceutical industry

"Securing our precursor licence represents a pivotal advantage for Optimi, offering a compelling edge in producing MDMA at significantly reduced costs," said Optimi Chief Financial Officer Jacob Safarik.

Key Points: 
  • "Securing our precursor licence represents a pivotal advantage for Optimi, offering a compelling edge in producing MDMA at significantly reduced costs," said Optimi Chief Financial Officer Jacob Safarik.
  • "With the AMA’s current procedural terminology ("CPT") III codes for psychedelic-assisted therapies now officially in effect, this underscores the goal of obtaining our precursor licence.
  • With the Company’s precursor licence secured, Optimi Chief Science Officer, Dr. Preston A.
  • Chase, is pleased to report the successful encapsulation of MDMA into 40mg and 60mg dosage formats after verification through its High-performance Liquid Chromatography (HPLC) methodology.